United States 116th Congress Status: Died 9 D cosponsors

HR 2734 — Safer Prescribing of Controlled Substances Act

Last action — Referred to the Subcommittee on Crime, Terrorism, and Homeland Security.

Track this bill free

No card. One bill, free forever — alerts when it moves.

  1. ✓
    Introduced
  2. ✓
    In Committee
  3. Died in session

This bill died with 116th Congress. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.

This bill is no longer active — its legislative session has ended, so there is no live prognosis. It would have to be reintroduced in the current session to move again.

Summary

Safer Prescribing of Controlled Substances Act This bill establishes a new registration requirement for a practitioner (other than a hospital, pharmacy, or veterinarian) who is licensed to dispense or conduct research with a controlled substance in schedules II, III, IV, or V of the Controlled Substances Act. Specifically, the practitioner must comply with a training requirement as a condition of obtaining or renewing their registration. The training must include information on best practices for pain management and responsible prescribing of pain medications.

Bill Text

Sections of law this bill changes

1 section in 1 law

From the bill's own amending language, matched to the official United States Code (current through Public Law 119-124).

Drug abuse prevention and control · 21 U.S.C. ch. 13 1 section
  • § 823 Registration requirements Amends

    21 U.S.C. § 823

    The law today

    (a) Manufacturers of controlled substances in schedule I or II The Attorney General shall register an applicant to manufacture controlled substances in schedule I or II if he determines that such registration is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. In determining the public interest, the following factors shall be considered: (1) maintenance of effective controls against diversion of particular controlled substances and any controlled substance in schedule I or II compounded therefrom into other than legitimate medical, scientific, research, or industrial channels, by limiting the importation and bulk manufacture of such controlled substances to a number of establishments which can produce an adequate and uninterrupted supply of these substances under adequately competitive conditions for legitimate medical, scientific, research, and industrial purposes; (2) compliance with applicable State and local law; (3) promotion of technical advances in the art of manufacturing these substances and the development of new substances; (4) prior conviction record of applicant under Federal and State laws relating to the manufacture, distribution, or dispensing of such substances; (5) past experience in the manufacture of controlled substances, and the existence in the establishment of effective control against diversion; and (6) such other factors as may be relevant to and consistent with the public health and safety. (b) Distributors of controlled substances in schedule I or II The Attorney General shall register an applicant to distribute a controlled substance in schedule I or II unless he determines that the issuance of such registration is inconsistent with the public interest. In determining the public interest, the following factors shall be considered: (1) maintenance of effective control against diversion of particular controlled substances into other than legitimate medical, scientific, and industrial channels; (2) compliance with applicable State and local law; (3) prior conviction record of applicant under Federal or State laws relating to the manufacture, distribution, or dispensing of such substances; (4) past experience in the distribution of controlled substances; and (5) such other factors as may be relevant to and consistent with the public health and safety. (c) Manufacturers of marijuana for research purposes (1) (A) As it relates to applications to manufacture marijuana for research purposes, when the Attorney General places a notice in the Federal Register to increase the number of entities registered under this chapter to manufacture marijuana to supply appropriately registered researchers in the United States, the Attorney General shall, not later than 60 days after the date on which the Attorney General receives a completed application— (i) approve the application; or (ii) request supplemental information. (B) For purposes of subparagraph (A), an application shall be deemed complete when the applicant has submitted documentation showing each of the following: (i) The requirements designated in the notice in the Federal Register are satisfied. (ii) The requirements under this chapter are satisfied. (iii) The applicant will limit the transfer and sale of any marijuana manufactured under this subsection— (I) to researchers who are registered under this chapter to conduct research with controlled substances in schedule I; and (II) for purposes of use in preclinical research or in a clinical investigation pursuant to an investigational new drug exemption under 355(i) 1 of this title. (iv) The applicant will transfer or sell any marijuana manufactured under this subsection only with prior, written consent for the transfer or sale by the Attorney General. (v) The applicant has completed the application and review process under subsection (a) for the bulk manufacture of controlled substances in schedule I....

    110 other bills also change this section · Follow it → Official text at uscode.house.gov ↗

How this bill changes current law

8 changes Share ↗

Compared against current U.S. Code AI-generated reading aid — verify against the official bill.

The bill adds new continuing education requirements for certain practitioners authorized to prescribe controlled substances.

  • 21 U.S.C. 823

    The Attorney General shall register → Subject to subsection (k), the Attorney General shall register

    This change establishes that subsection (k) must be considered when registering practitioners.

  • 21 U.S.C. 823

    (k)(1) In this subsection, the term `covered practitioner' means a practitioner that is not a hospital, pharmacy, or veterinarian.

    Defines what qualifies as a 'covered practitioner' for the new training requirements.

  • 21 U.S.C. 823

    (2) As a condition of granting or renewing the registration of a covered practitioner under this part to dispense, or conduct research with, controlled substances in schedule II, III, IV, or V, the Attorney General shall require the covered practitioner to complete training through accredited continuing prescriber education that the Secretary of Health and Human Services determines meets the requirements under paragraph (3), unless the covered practitioner meets the conditions described in paragraph (6).

    Establishes mandatory training requirements for covered practitioners before they can be registered or have their registration renewed.

  • 21 U.S.C. 823

    (3) The training provided for purposes of paragraph (2) shall, at a minimum, expose covered practitioners to-- (A) best practices for pain management, including responsible prescribing of pain medications, alternatives to prescribing controlled substances and other alternative therapies to decrease the use of opioids; (B) tools to manage adherence and diversion of controlled substances, including prescription drug monitoring programs, drug screening, informed consent, overdose education, and the use of opioid overdose antagonists; and (C) best practices for substance use disorder treatment, including methods for diagnosing, treating, and managing a substance use disorder, including the use of medications approved by the Food and Drug Administration and evidence-based nonpharmacological therapies, and linking patients to evidence-based treatment for substance use disorders.

    Specifies the content and topics that the continuing education training must cover.

  • 21 U.S.C. 823

    (4) The Substance Abuse and Mental Health Services Administration shall establish or support the establishment of not less than 1 training module that meets the requirements under paragraph (3) that is provided-- (A) to any covered practitioner registered or applying for a registration under this part to dispense, or conduct research with, controlled substances in schedule II, III, IV, or V; (B) online; and (C) free of charge.

    Mandates the creation of a training module that meets the specified educational requirements for practitioners.

  • 21 U.S.C. 823

    (5) The Secretary of Health and Human Services shall establish, maintain, and periodically update a publicly available database providing information relating to training modules that meet the requirements under paragraph (3).

    Requires creation of a public database to provide information about approved training modules.

  • 21 U.S.C. 823

    (6) A covered practitioner shall be deemed as completing the training described in paragraph (2) if the covered practitioner completes accredited continuing prescriber education, that-- (A) is required, as a condition of State practice licensure, to fulfill mandated training or education related to best practices in pain management and substance use disorder treatment, that is substantially similar to the requirements described in paragraph (3); or (B) is required, as a condition of maintaining a board certification recognized by the appropriate board certification organizations for the covered prescriber to fulfill mandated training or education related to best practices in pain management and substance use disorder treatment, that is substantially similar to the requirement described in paragraph (3).

    Allows covered practitioners to fulfill the training requirement through state licensure or board certification if it meets specified criteria.

  • 21 U.S.C. 823

    (7) Not later than 5 years after the date of enactment of the Safer Prescribing of Controlled Substances Act, the Secretary of Health and Human Services shall evaluate, and make publicly available a report describing, how exposure to the training required under this subsection has changed prescribing patterns of controlled substances.

    Requires a report to assess the effectiveness of the mandated training on prescribing practices.

Action History

  1. Referred to the Subcommittee on Crime, Terrorism, and Homeland Security.

  2. Referred to the Subcommittee on Health.

  3. Introduced in House

  4. Introduced in House

  5. Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

  6. Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 8 co-sponsors · 538 not signed on

Sponsors (1)

Co-sponsors (8)

Not signed on (538)

538 members have not signed on to this bill.

Show all 538 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

public-safety healthcare
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

What does HR 2734 do?
Safer Prescribing of Controlled Substances Act This bill establishes a new registration requirement for a practitioner (other than a hospital, pharmacy, or veterinarian) who is licensed to dispense or conduct research with a controlled substance in schedules II, III, IV, or V of the Controlled Substances Act. Specifically, the practitioner must comply with a training requirement as a condition of obtaining or renewing their registration. The training must include information on best practices for pain management and responsible prescribing of pain medications.
Who sponsors HR 2734?
HR 2734 is sponsored by Johnson, Eddie Bernice (Democratic), Clarke, Yvette D. (Democratic), Tonko, Paul (Democratic), Trone, David J. (Democratic), Scanlon, Mary Gay (Democratic), Luria, Elaine G. (Democratic), Hayes, Jahana (Democratic), Spanberger, Abigail Davis (Democratic), and Trahan, Lori (Democratic).
What is the current status of HR 2734?
This bill died with 116th Congress. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
Where can I track HR 2734?
Track HR 2734 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on HR 2734

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of HR 2734

Last checked for changes 3 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →